Persistent dysglycemia is associated with unfavorable treatment outcomes in patients with pulmonary tuberculosis from Peru

Detalhes bibliográficos
Autor(a) principal: Calderon, Roger I
Data de Publicação: 2022
Outros Autores: Arriaga, María B, Aliaga, Juan G, Barreda, Nadia N, Sanabria, Oswaldo M, Duarte, Beatriz Barreto, Franco, João Pedro Duarte, Lecca, Leonid, Andrade, Bruno B, Carvalho, Anna Cristina Calçada, Kritski, Afrânio L
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Repositório Institucional da FIOCRUZ (ARCA)
Texto Completo: https://www.arca.fiocruz.br/handle/icict/51488
Resumo: Consejo Nacional de Ciencia, Tecnología e Innovación Tecnológica (CONCYTEC- Peru) / Fondo Nacional de Desarrollo Científico, Tecnológico y de Innovación Tecnológica. Centro Internacional Fogarty e Instituto Nacional de Saúde Infantil e Desenvolvimento Humano dos Institutos Nacionais de Saúde. Fundação de Amparo à Pesquisa da Bahia (FAPESB). Coordenação de Aperfeiçoamento de Pessoal de Nível Superior. Institutos Nacionais de Saúde dos Estados Unidos, NIH, Bethesda. Programa de Pesquisa Intramuros da FIOCRUZ. Institutos Nacionais de Saúde. Secretaria de Ciência e Tecnologia (SCTIE). Ministério da Saúde (MS). Conselho Nacional de Desenvolvimento Científico e Tecnológico.
id CRUZ_86e88c01c240ca19d70ed80f9e45bd60
oai_identifier_str oai:www.arca.fiocruz.br:icict/51488
network_acronym_str CRUZ
network_name_str Repositório Institucional da FIOCRUZ (ARCA)
repository_id_str 2135
spelling Calderon, Roger IArriaga, María BAliaga, Juan GBarreda, Nadia NSanabria, Oswaldo MDuarte, Beatriz BarretoFranco, João Pedro DuarteLecca, LeonidAndrade, Bruno BCarvalho, Anna Cristina CalçadaKritski, Afrânio L2022-02-25T14:11:04Z2022-02-25T14:11:04Z2022Calderon, Roger I. et. al. Persistent dysglycemia is associated with unfavorable treatment outcomes in patients with pulmonary tuberculosis from Peru. International Journal of Infectious Diseases, v.116, p. 293–301, 2022.1201-9712https://www.arca.fiocruz.br/handle/icict/51488doi.org/10.1016/j.ijid.2022.01.012Consejo Nacional de Ciencia, Tecnología e Innovación Tecnológica (CONCYTEC- Peru) / Fondo Nacional de Desarrollo Científico, Tecnológico y de Innovación Tecnológica. Centro Internacional Fogarty e Instituto Nacional de Saúde Infantil e Desenvolvimento Humano dos Institutos Nacionais de Saúde. Fundação de Amparo à Pesquisa da Bahia (FAPESB). Coordenação de Aperfeiçoamento de Pessoal de Nível Superior. Institutos Nacionais de Saúde dos Estados Unidos, NIH, Bethesda. Programa de Pesquisa Intramuros da FIOCRUZ. Institutos Nacionais de Saúde. Secretaria de Ciência e Tecnologia (SCTIE). Ministério da Saúde (MS). Conselho Nacional de Desenvolvimento Científico e Tecnológico.Socios En Salud Sucursal Peru. Lima, Peru / Universidade Federal do Rio de Janeiro. Faculdade de Medicina. Programa Acadêmico de Tuberculose. Rio de Janeiro, RJ, Brasil / Universidad Nacional Federico Villarreal. Grupo de Investigación en Bioquímica y Biología Sintética. Lima, Peru.Fundação Oswaldo Cruz. Instituto Gonçalo Moniz. Salvador, BA, Brasil / Universidade Federal da Bahia. Faculdade de Medicina. Salvador, BA, Brasil / Multinational Organization Network Sponsoring Translational and Epidemiological Research Initiative. Salvador, BA, Brasil / Fundação José Silveira. Instituto Brasileiro para Investigação da Tuberculose. Salvador, BA, Brasil.Socios En Salud Sucursal Peru. Lima, Peru.Socios En Salud Sucursal Peru. Lima, Peru.Socios En Salud Sucursal Peru. Lima, Peru.Multinational Organization Network Sponsoring Translational and Epidemiological Research Initiative. Salvador, BA, Brasil / Fundação Oswaldo Cruz . Instituto Gonçalo Moniz. Laboratório de Inflamação e Biomarcadores. Salvador, BA, Brasil / Universidade Salvador. Curso de Medicina. Salvador, BA, Brasil.Multinational Organization Network Sponsoring Translational and Epidemiological Research Initiative. Salvador, BA, Brasil / Universidade Salvador. Curso de Medicina. Salvador, BA, Brasil.Socios En Salud Sucursal Peru. Lima, Peru / Universidade Salvador. Curso de Medicina. Salvador, BA, Brasil.Multinational Organization Network Sponsoring Translational and Epidemiological Research Initiative. Salvador, BA, Brasil / Fundação Oswaldo Cruz . Instituto Gonçalo Moniz. Laboratório de Inflamação e Biomarcadores. Salvador, BA, Brasil / Socios En Salud Sucursal Peru. Lima, Peru / Universidade Salvador. Curso de Medicina. Salvador, BA, Brasil / Faculdade de Medicina, Universidade Federal da Bahia, Salvador, BA, Brasil / Escola Bahiana de Medicina e Saúde Pública. Curso de Medicina. Salvador, BA, Brasil / Division of Infectious Diseases. Department of Medicine. Vanderbilt University School of Medicine. Nashville, Tennessee, USA.Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Inovações em Terapias, Ensino e Bioprodutos. Rio de Janeiro, RJ, Brasil.Universidade Federal do Rio de Janeiro. Faculdade de Medicina. Programa Acadêmico de Tuberculose. Rio de Janeiro, RJ, Brasil.Background: Dysglycemia (i.e., prediabetes or diabetes) in patients with tuberculosis (PWTB) is associated with increased odds of mortality and treatment failure. Whether such association holds true when dysg- lycemia is transient or persistent is unknown. In this study, we tested the association between persistent dysglycemia (PD) during anti-tuberculosis (TB) treatment and unfavorable treatment outcomes in PWTB from Lima, Peru. Methods: PWTB enrolled between February and November 2017 were followed for 24-months. Dysg- lycemia was measured through fasting glucose and HbA1c at baseline during the 2 nd - and 6 th -month of TB treatment. PD was defined as dysglycemia detected in 2 different visits. The association between PD and unfavorable TB treatment outcome was evaluated using logistic regression. Results: Among 125 PWTB, PD prevalence was 29.6%. PD was associated with more lung lesion types, higher bacillary loads, low hemoglobin (Hb), and high body mass index (BMI). Unfavorable TB treatment outcome was associated with older age, higher BMI, more lung lesion types, and PD. After adjusting for age, Hb levels, smoking, and smear grade, PD was independently associated with unfavorable treatment outcomes (adjusted odds ratio (aOR): 6.1; 95% CI: 1.9–19.6). Conclusion: PD is significantly associated with higher odds of unfavorable TB treatment outcomes. Dysg- lycemia control duringengElsevierTuberculose PulmonarAntituberculososTuberculosis, PulmonaryAntitubercular AgentsTuberculosis PulmonarAntituberculososTuberculose pulmonaireAntituberculeuxPersistent dysglycemia is associated with unfavorable treatment outcomes in patients with pulmonary tuberculosis from Peruinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleinfo:eu-repo/semantics/openAccessreponame:Repositório Institucional da FIOCRUZ (ARCA)instname:Fundação Oswaldo Cruz (FIOCRUZ)instacron:FIOCRUZLICENSElicense.txtlicense.txttext/plain; charset=utf-82991https://www.arca.fiocruz.br/bitstream/icict/51488/1/license.txt5a560609d32a3863062d77ff32785d58MD51ORIGINALCalderon, I. R. Persistent...pdfCalderon, I. R. Persistent...pdfapplication/pdf1752404https://www.arca.fiocruz.br/bitstream/icict/51488/2/Calderon%2c%20I.%20R.%20Persistent...pdf2c149e643a7cef4149379d27f41a4426MD52icict/514882023-03-15 14:33:11.904oai:www.arca.fiocruz.br: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ório InstitucionalPUBhttps://www.arca.fiocruz.br/oai/requestrepositorio.arca@fiocruz.bropendoar:21352023-03-15T17:33:11Repositório Institucional da FIOCRUZ (ARCA) - Fundação Oswaldo Cruz (FIOCRUZ)false
dc.title.pt_BR.fl_str_mv Persistent dysglycemia is associated with unfavorable treatment outcomes in patients with pulmonary tuberculosis from Peru
title Persistent dysglycemia is associated with unfavorable treatment outcomes in patients with pulmonary tuberculosis from Peru
spellingShingle Persistent dysglycemia is associated with unfavorable treatment outcomes in patients with pulmonary tuberculosis from Peru
Calderon, Roger I
Tuberculose Pulmonar
Antituberculosos
Tuberculosis, Pulmonary
Antitubercular Agents
Tuberculosis Pulmonar
Antituberculosos
Tuberculose pulmonaire
Antituberculeux
title_short Persistent dysglycemia is associated with unfavorable treatment outcomes in patients with pulmonary tuberculosis from Peru
title_full Persistent dysglycemia is associated with unfavorable treatment outcomes in patients with pulmonary tuberculosis from Peru
title_fullStr Persistent dysglycemia is associated with unfavorable treatment outcomes in patients with pulmonary tuberculosis from Peru
title_full_unstemmed Persistent dysglycemia is associated with unfavorable treatment outcomes in patients with pulmonary tuberculosis from Peru
title_sort Persistent dysglycemia is associated with unfavorable treatment outcomes in patients with pulmonary tuberculosis from Peru
author Calderon, Roger I
author_facet Calderon, Roger I
Arriaga, María B
Aliaga, Juan G
Barreda, Nadia N
Sanabria, Oswaldo M
Duarte, Beatriz Barreto
Franco, João Pedro Duarte
Lecca, Leonid
Andrade, Bruno B
Carvalho, Anna Cristina Calçada
Kritski, Afrânio L
author_role author
author2 Arriaga, María B
Aliaga, Juan G
Barreda, Nadia N
Sanabria, Oswaldo M
Duarte, Beatriz Barreto
Franco, João Pedro Duarte
Lecca, Leonid
Andrade, Bruno B
Carvalho, Anna Cristina Calçada
Kritski, Afrânio L
author2_role author
author
author
author
author
author
author
author
author
author
dc.contributor.author.fl_str_mv Calderon, Roger I
Arriaga, María B
Aliaga, Juan G
Barreda, Nadia N
Sanabria, Oswaldo M
Duarte, Beatriz Barreto
Franco, João Pedro Duarte
Lecca, Leonid
Andrade, Bruno B
Carvalho, Anna Cristina Calçada
Kritski, Afrânio L
dc.subject.other.pt_BR.fl_str_mv Tuberculose Pulmonar
Antituberculosos
topic Tuberculose Pulmonar
Antituberculosos
Tuberculosis, Pulmonary
Antitubercular Agents
Tuberculosis Pulmonar
Antituberculosos
Tuberculose pulmonaire
Antituberculeux
dc.subject.en.pt_BR.fl_str_mv Tuberculosis, Pulmonary
Antitubercular Agents
dc.subject.es.pt_BR.fl_str_mv Tuberculosis Pulmonar
Antituberculosos
dc.subject.fr.pt_BR.fl_str_mv Tuberculose pulmonaire
Antituberculeux
description Consejo Nacional de Ciencia, Tecnología e Innovación Tecnológica (CONCYTEC- Peru) / Fondo Nacional de Desarrollo Científico, Tecnológico y de Innovación Tecnológica. Centro Internacional Fogarty e Instituto Nacional de Saúde Infantil e Desenvolvimento Humano dos Institutos Nacionais de Saúde. Fundação de Amparo à Pesquisa da Bahia (FAPESB). Coordenação de Aperfeiçoamento de Pessoal de Nível Superior. Institutos Nacionais de Saúde dos Estados Unidos, NIH, Bethesda. Programa de Pesquisa Intramuros da FIOCRUZ. Institutos Nacionais de Saúde. Secretaria de Ciência e Tecnologia (SCTIE). Ministério da Saúde (MS). Conselho Nacional de Desenvolvimento Científico e Tecnológico.
publishDate 2022
dc.date.accessioned.fl_str_mv 2022-02-25T14:11:04Z
dc.date.available.fl_str_mv 2022-02-25T14:11:04Z
dc.date.issued.fl_str_mv 2022
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.citation.fl_str_mv Calderon, Roger I. et. al. Persistent dysglycemia is associated with unfavorable treatment outcomes in patients with pulmonary tuberculosis from Peru. International Journal of Infectious Diseases, v.116, p. 293–301, 2022.
dc.identifier.uri.fl_str_mv https://www.arca.fiocruz.br/handle/icict/51488
dc.identifier.issn.pt_BR.fl_str_mv 1201-9712
dc.identifier.doi.none.fl_str_mv doi.org/10.1016/j.ijid.2022.01.012
identifier_str_mv Calderon, Roger I. et. al. Persistent dysglycemia is associated with unfavorable treatment outcomes in patients with pulmonary tuberculosis from Peru. International Journal of Infectious Diseases, v.116, p. 293–301, 2022.
1201-9712
doi.org/10.1016/j.ijid.2022.01.012
url https://www.arca.fiocruz.br/handle/icict/51488
dc.language.iso.fl_str_mv eng
language eng
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.publisher.none.fl_str_mv Elsevier
publisher.none.fl_str_mv Elsevier
dc.source.none.fl_str_mv reponame:Repositório Institucional da FIOCRUZ (ARCA)
instname:Fundação Oswaldo Cruz (FIOCRUZ)
instacron:FIOCRUZ
instname_str Fundação Oswaldo Cruz (FIOCRUZ)
instacron_str FIOCRUZ
institution FIOCRUZ
reponame_str Repositório Institucional da FIOCRUZ (ARCA)
collection Repositório Institucional da FIOCRUZ (ARCA)
bitstream.url.fl_str_mv https://www.arca.fiocruz.br/bitstream/icict/51488/1/license.txt
https://www.arca.fiocruz.br/bitstream/icict/51488/2/Calderon%2c%20I.%20R.%20Persistent...pdf
bitstream.checksum.fl_str_mv 5a560609d32a3863062d77ff32785d58
2c149e643a7cef4149379d27f41a4426
bitstream.checksumAlgorithm.fl_str_mv MD5
MD5
repository.name.fl_str_mv Repositório Institucional da FIOCRUZ (ARCA) - Fundação Oswaldo Cruz (FIOCRUZ)
repository.mail.fl_str_mv repositorio.arca@fiocruz.br
_version_ 1813008927805145088

Registros relacionados